SHUBHAM PANT to Neoplasm Recurrence, Local
This is a "connection" page, showing publications SHUBHAM PANT has written about Neoplasm Recurrence, Local.
Connection Strength
0.256
-
Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab. J Oncol Pharm Pract. 2015 Jun; 21(3):232-7.
Score: 0.130
-
Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nat Med. 2024 Feb; 30(2):531-542.
Score: 0.064
-
Association of major stressors with elevated risk of breast cancer incidence or relapse. Drugs Today (Barc). 2009 Feb; 45(2):115-26.
Score: 0.023
-
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer. Gynecol Oncol. 2023 01; 168:76-82.
Score: 0.015
-
Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase?II Trial. Adv Ther. 2021 08; 38(8):4581-4591.
Score: 0.014
-
PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2016 10; 61:31-40.
Score: 0.010